Results 81 to 90 of about 55,554 (173)
Objective To explore the adjustment and impact of chronic kidney disease-mineral and bone disorder (CKD-MBD) parameters in maintenance dialysis patients utilizing the Doctor-Patient Care App (Renal Care App).
Gulimire Muhetaer +6 more
doaj +1 more source
Developing an in vitro model of CKD-MBD induced αKlotho suppression
Chronic Kidney Disease (CKD) affects approximately 1 in 10 Americans. Diabetic nephropathy is also associated with the development of chronic kidney disease-mineral bone disorder (CKD-MBD).
LaFave, Nicole, OMS-2 +5 more
core
The KDIGO 2017 Clinical Practice Guideline Update for the Diagnosis, Evaluation, Prevention, and Treatment of CKD-MBD represents a selective update of the prior CKD-MBD Guideline published in 2009.
Linda McCann +23 more
core +1 more source
Developing an In Vitro Model of CKD-MBD Induced αKlotho Suppression
Chronic Kidney Disease (CKD) affects approximately 1 in 10 Americans. Diabetic nephropathy is also associated with the development of chronic kidney disease-mineral bone disorder (CKD-MBD).
Waite, Timothy, OMS-2 +3 more
core
: Canonical Wnt signaling activity contributes to physiological and adaptive bone mineralization and is an essential player in bone remodeling. Sclerostin is a prototypic soluble canonical Wnt signaling pathway inhibitor that is produced in osteocytes ...
Neven, Ellen +9 more
core +1 more source
Nel caso clinico descritto viene valutato un paziente affetto da CKD (grado V K/DOQI), con iperparatiroidismo ipocalcemico non migliorato dall'avvio della terapia emodialitica, dall'uso di supplementi di calcio carbonato e di un analogo della vitamina D.
Maria Polidoro
doaj +1 more source
Male Cy/+ rats have shown a relatively consistent pattern of progressive kidney disease development that displays multiple key features of late stage chronic kidney disease-mineral bone disorder (CKD-MBD), specifically the development of cortical bone ...
Allen, Matthew R. +7 more
core +1 more source
Baseline characteristics overall and by facility-level proportions of patients with at least two of three CKD-MBD biomarkers out of or above target ranges, using a PTH target range of 150â300Â pg/mL.
Mark Danese (590389) +9 more
core +1 more source
33. PENATALAKSANAAN CHRONIC KIDNEY DISEASE-MINERAL AND BONE DISORDER (CKD-MBD)
33.
HAERANI RASYID, HAERANI RASYID
core

